CR Bard

U.S. sales growth more than compensates for currency-driven hit on OUS revenue

Lutonix® DCB is one step closer to becoming the first FDA-approved drug coated balloon for the treatment of patients with femoropopliteal occlusive disease following the FDA Circulatory devices panel vote.

So CryoLife had a stake in hemostat maker Medafor. Medafor sells up to CR Bard, giving CryoLife a very healthy return on its investment. Even better is the fact that it has its own hemostat already out there in certain markets and en route to US approval.

C. R. Bard, Inc. is to acquire privately-held Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. The purchase price of $200 million will be paid at closing, expected to occur later this year, and future contingent payments up to an additional $80 million are based on specific revenue-based milestones through June 30, 2015.

Neomend reckons its PEG-based spray-on sealant has many applications. Presumably so does Bard, which has just announced the purchase of the California-based outfit.

C. R. Bard, Inc’s acquisition of Lutonix, Inc will position it well to be the first company to gain FDA clearance for a drug coated PTA balloon in what is estimated could be a $1Bn market.

C. R. Bard, Inc. senior vice president and chief financial officer, Todd C. Schermerhorn will retire after a transition period that is expected to run until the end of August 2012.

Clearstream Technologies has agreed to be sold to Bard for 85p a share